Search This Blog

Monday, December 14, 2020

FedEx gains as confidence on the shipper grows ahead of earnings

 

  • Credit Suisse lifts estimates on FedEx (NYSE:FDX) after taking into account accelerating e-commerce trends and a peak season that could prove to be stronger and longer than anticipated.
  • "We are now dialing in higher peak surcharge revs for both Q2 and Q3. We further note that FDX typically incurs the bulk of cost related to the peak season ramp in Q2, while the revs are often shifted into Q3 (this was particularly true in 2Q20, given the late timing of Cyber week). As such, we now are modeling for Q2 Ground margins of 9.5% (vs. prev 8.8%), marking the first time in 8 qtrs of y/y improvement. Underpinning this are our assumptions of +4% in rev/piece (vs prev +3%) and cost/piece inflation of +20bps (vs. prior +60bps)."
  • The firm expects FQ2 EPS of $4.14 vs. $3.25 prior and $3.94 consensus. CS sees FY21 EPS of $17.02 vs. $15.68 prior and $16.20 consensus.
  • An Outperform rating on FedEx on the shipper and price target of $365 is kept in place.
  • Shares of FedEx are up 2.25% in premarket action to $295.99.
  • FedEx has topped consensus earnings marks three quarters in a row.
  • https://seekingalpha.com/news/3643952-fedex-gains-confidence-on-shipper-grows-ahead-of-earnings

Acceleron's sotatercept nabs Orphan Drug tag for PAH in Europe

 

  • The European Commission has granted Orphan Designation to Acceleron Pharma's (NASDAQ:XLRN) sotatercept for the treatment of pulmonary arterial hypertension (PAH).
  • The company is currently advancing a Phase 3 trial for sotatercept, beginning with the registrational trial known as STELLAR expected to initiate by the end of this year.
  • Sotatercept is part of a licensing agreement with Bristol Myers Squibb, and a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling, which is a key molecular driver of pulmonary arterial hypertension.
  • https://seekingalpha.com/news/3643957-accelerons-sotatercept-nabs-orphan-drug-tag-for-pah-in-europe

Amarin up on encouraging Vascepa data in COVID-19, cardiovascular events

 

  • Amarin (NASDAQ:AMRN) rises 7% after announcing VASCEPA (icosapent ethyl)-related scientific findings during the NLA Scientific Sessions 2020, held from December 10 – 12, 2020.
  • Following administration of VASCEPA, a unique prescription eicosapentaenoic acid (EPA)-based therapy at 4 g/day in the successful REDUCE-IT cardiovascular outcomes study, analysis shows that median serum EPA levels increased in year 1 to well over 100 ug/mL (144 μg/mL; p=1x10-30) and increased ~400% across the study from baseline (26.1 μg/mL) versus placebo. Docosahexaenoic acid levels were measured and showed a decrease of 2.9% (p=0.002).
  • On-treatment EPA levels in the VASCEPA group were strongly associated with reduced cardiovascular events, including benefits observed in the primary and key secondary endpoints.
  • The VASCEPA COVID-19 CardioLink-9 Trial enrolled 100 SARS-CoV-2 positive and symptomatic outpatients. Patients in the VASCEPA arm received a loading dose of 8 g/day for 3 days followed by 4 g/day for 11 days on top of usual care. Patients randomized to the non-active arm received usual care. Baseline characteristics were comparable between groups.
  • The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation. Within-group changes in D-dimer were also examined.
  • VASCEPA administration resulted in a 25% reduction in hsCRP (p=0.011) as well as a reduction in D-dimer (p=0.048).
  • Additionally, VASCEPA administration resulted in a significant 52% reduction of the total FLU-PRO prevalence score as compared to a 24% reduction in the usual care group (p=0.003 between groups), with reductions across individual score domains, including a significantly larger reduction compared to usual care in the body/systemic domain (54% vs. 26%; p=0.003).
  • Significant reductions in the FLU-PRO symptom score compared to usual care were also observed in the total symptom score (p=0.003), as well as in the body/systemic (p=0.0007) and chest/respiratory (p=0.01) domains.
  • These results have not yet been published or reviewed by regulatory authorities. Additional study is needed.
  • VASCEPA COVID-19 CardioLink-9 trial is the first in a series of ongoing studies into the potential role of VASCEPA therapy in COVID-19 settings. Other ongoing trials include PREPARE-IT: Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial and A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE) sponsored by Kaiser Permanente.
  • Other Amarin-supported abstracts on REDUCE-IT study and providing mechanism of action insights were also presented.
  • The company will host a webcast today at 8:00 a.m. EST to further discuss these and other VASCEPA-related findings.
  • https://seekingalpha.com/news/3643938-amarin-up-7-on-encouraging-vascepa-data-in-covidminus-19-and-cardiovascular-events

Sunday, December 13, 2020

NJ to give first doses of COVID-19 vaccine on Tuesday

 New Jersey will dole out its first doses of the COVID-19 vaccine Tuesday morning in Newark, Gov. Phil Murphy announced Sunday.

The governor said the vaccination kick-off will be held at University Hospital.

“We will begin vaccinating our heroic healthcare workers,” Murphy told ABC anchor Martha Raddatz on “This Week.”

Murphy said the “majority” of the 76,000 doses sent to the Garden State will be administered to healthcare workers, followed by nursing-home residents and staff.

“Split the majority towards healthcare workers, but a good slug toward our long-term care residents and staff,” Murphy said.

“And then with each ensuing week, those are the two top priorities, and it’ll take us a number of weeks, as you can image, to work through the entire populations in both of those groups,” he added.

The governor said the general masses should have access by spring.

“I think by April, May, everybody will have access to one of these vaccines,” Murphy said.

The federal Food and Drug Administration approved Pfizer’s vaccine for emergency use Friday.

Moderna’s vaccine could be the next shipped out, after it asked for emergency use authorization late last month.

https://nypost.com/2020/12/13/nj-to-give-first-doses-of-covid-19-vaccine-on-tuesday/

NY set to receive COVID-19 vaccines by Monday, administer within hours

 The first shipment of Pfizer’s coronavirus vaccine will touch down in New York by Monday — and healthcare workers could be getting their shots within hours of arrival. 

The Empire State is awaiting 170,000 doses — 72,000 of which will go to New York City — after the first shipments left a Pfizer facility in Michigan earlier Sunday.

“Hope is on the way, and it’s departing from Kalamazoo, Michigan,” Gov. Andrew Cuomo tweeted along with a video of trucks leaving the warehouse.

“We are getting closer to the finish line,” the governor said.

The vaccines are expected to arrive at several FedEx locations, including one in Hunts Point in The Bronx, before being sent out statewide, WABC-TV reported.

The FedEx locations are equipped with freezers to keep the shots at the extremely cold temperatures required, the outlet said.

But the company is hoping the freezers won’t be necessary, as it is working to ship the shots to their final destination as quickly as possible.

New York’s initial shipment is anticipated to flow to 90 different cold-storage sites statewide in the coming days, Cuomo has said.

It is unclear how many doses each site will get.

The Post previously reported that each of Mount Sinai’s seven hospitals is expecting to receive at least 975 doses, while BronxCare network, which runs Bronx-Lebanon Hospital, is set for 8,000 doses.

Healthcare workers and nursing-home residents will be the first to get the shots as soon as Monday.

Two staffers from Northwell Health’s facilities will be vaccinated during a press conference at Long Island Jewish Medical Center in Queens on Monday, The Post has learned.

Meanwhile, on Sunday, workers at the city’s Elmhurst Hospital in Queens were abuzz about the vaccine news and said they were expecting a shipment to arrive by Monday.

“We were all talking about it this morning,” an emergency room nurse told The Post, though she added, “They haven’t asked us for volunteers [to receive it] or told us anything.”

A nurse at NewYork-Presbyterian Hospital in Lower Manhattan said that she was “excited” about taking the shot.

“I’m definitely going to get it,” she said.

But at Mount Sinai Beth Israel, an ER nurse was more guarded, saying, “I’m all for vaccines, but we still have much more to learn.”

“We will just wait and see and hope for the best,” she said.

Officials in the Big Apple said they would be setting up a “vaccine command center” across the street from City Hall to report on the distribution process and build trust with the community about the inoculation.

https://nypost.com/2020/12/13/fedex-location-in-the-bronx-awaiting-pfizers-covid-vaccine-shipment/

Hoyer suggests Dems might do without state, local aid for COVID-19 relief

 The U.S. House of Representatives’ No. 2 Democrat, Steny Hoyer, suggested on Sunday his party might be willing to accept a coronavirus relief deal without the state and local aid that Democrats have been insisting should be part of it.

Democrats “are not going to get everything we want. We think state and local (aid) is important. And if we can get that, we want to get it. But we want to get aid out to the people who are really, really struggling and are at grave risk,” Hoyer, the House majority leader, told CNN.

Congressional negotiators have been trying for months to reach agreement on a new coronavirus aid bill, after Congress approved $3 trillion in relief earlier this year.

Leading lawmakers would like to attach the COVID-19 aid package to a massive bill funding the government that needs to be done by Friday.

Senate Majority Leader Mitch McConnell, a Republican, suggested last week scrapping aid to state and local governments - a Democratic priority that many Republicans oppose - as well as liability protections for business - a Republican priority opposed by many Democrats - in order to break the stalemate.

But House Speaker Nancy Pelosi and Senate Democratic leader Chuck Schumer rejected that idea last week, saying that dropping new aid to state and local governments would put at risk the jobs of police, firefighters and other frontline public workers battling the COVID-19 pandemic.

There was no immediate comment from Pelosi’s or Schumer’s office on Sunday.

https://www.reuters.com/article/us-health-coronavirus-usa-congress/hoyer-suggests-u-s-democrats-might-do-without-state-local-aid-for-covid-19-relief-idUSKBN28N0U8

To stimulate economic recovery, the Fed needs to get out of its own way

 The media are focused on fiscal policy failures—namely, the fight over a second Covid economic-relief bill. They should be paying much closer attention to monetary policy.

The neglect is due to the long-running sense that, with interest rates down nearly to zero and financial markets flooded with liquidity, monetary policy has done all it can to spur growth. But a closer look at Fed policy and practice shows why the central bank’s efforts to stimulate economic activity have fallen short. It can still fix the problem.

As a first step, the Fed should abandon its still relatively new practice of paying interest on the reserves it holds for banks. First adopted in 2008 in imitation of Europe, where the practice also distorts policy effects, these payments tempt banks to leave money idle in deposits instead of using it to lend funds to businesses and individuals. Before the Fed began paying interest on reserves, banks made a thorough use of their reserves to support such lending. They held only as much in these accounts as regulations required, eagerly lending the rest to individuals and businesses, large and small, to finance spending on new equipment, the latest technologies, and hiring.

The Fed’s own accounting gives ample evidence of the extent of the problem. Prior to 2008, banks possessed minimal reserves. Since then, reserves held back from lending have risen astronomically. Over the last 12 months or so, 91 percent of funds held by banks at the Fed exceeded required amounts. Money held back this way means credit denied to the businesses and individuals that move the economy.

Though the data speak clearly, the Fed seems unaware of the problem. Perhaps the banks have lobbied it to continue the practice. The Fed gave a hint of recognition a few months ago, when policymakers lowered the rate paid on reserves below what banks can get from low-risk lending elsewhere, but mostly policymakers have tried to get around the problem by bypassing the banks and injecting liquidity directly into financial markets. But buying government and corporate bonds on the open market, or quantitative easing, has also failed. Rather than reaching “Main Street,” where this torrent of money could have stimulated economic activity, the liquidity that the Fed has added to financial markets has merely bid up the prices of financial assets, quite apart from what was happening in the general economy.

An exceedingly cautious regulatory climate—a result of lessons learned in the 2008 financial crisis—has also blocked the flow of credit to the real economy. The Dodd-Frank financial reform, for example, penalizes banks that lend to business, especially small businesses. Because such lending carries greater risk than, say, buying government securities or simply leaving funds idle in Fed deposits, the law insists that banks set aside more capital than they otherwise would, denying them the high returns they would get from such lending. At the same time, the law orders the Fed to impose “stress tests” on the banks. Any risky loans—like those to small businesses and individuals—make the banks look less stress-resistant, which weakens their stock price. Though policymakers must see the effect, Congress seems to prefer playing it safe instead of allowing banks to take the risk of financing economic growth.

The Fed’s preference for using near-zero interest rates to stimulate economic activity has also had a perverse effect. In theory, reducing to nothing the cost banks incur from collecting deposits will encourage them to lend more freely and at more attractive rates to individuals looking to make big-ticket purchases, or to businesses that want to expand. In practice, however, the policy has made it especially attractive for banks to buy government bonds instead of making these economically important loans.

For instance, only two years ago, banks paid an average of about 1.3 percent to gather deposits, while earning 2.25 percent on a five-year Treasury note—a spread that allowed them to earn a 73 percent return, risk-free. Today, banks pay on average 0.09 percent on customer deposits and get a 0.32 percent return from a five-year Treasury note: a 156 percent return. The numbers are even better for ten-year bonds. No wonder the banks prefer lending to the Treasury over lending to small businesses. They earn an outrageous premium over cost, take no credit risk, and win points from regulators for playing it safe.

These preferences show clearly in the mix of bank assets recently reviewed by The American Banker. The 25 largest banks in the U.S. have seen a massive $1.3 trillion inflow of deposits since last February. They have used almost all of it to add $1.1 trillion to their holdings of cash and securities guaranteed by the federal government, mostly Treasury notes and bonds. Treasury paper now constitutes some 35 percent of their assets, the biggest share since record-keeping started in 1985. At the same time, a survey conducted regularly by the Fed indicates that banks have significantly tightened their standards for lending to small businesses and individuals.

Because the Fed has failed to clean up this mess, it has also failed to achieve anything close to the stated aim of stimulating economic growth. Before monetary policymakers dramatically announce yet another tidal wave of money, they should find a way to fix these self-defeating policies.